The FDA has boosted treatment options for sickle cell disease by approving voxeletor for adults and adolescents aged 12 years or older who have the illness.
Marketed as Oxbryta, the drug “is an inhibitor of deoxygenated sickle hemoglobin polymerization, which is the central abnormality in sickle cell disease,” Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence, said in a statement. When patients take the medication “sickle cells are less likely to bind together and form the sickle shape, which can cause low hemoglobin levels due to red blood cell destruction,” Pazdur added.
Voelker R. New Option for Sickle Cell Disease. JAMA. 2020;323(1):18. doi:10.1001/jama.2019.20640
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: